A Phase 2 interventional study of Alirocumab in Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 34 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.
Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 11th largest by enrollment, is one of 2 that started in 2026, is one of 9 in phase 2, and was the 42nd registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 438 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 107 across the 43 interventional studies. Of the 40 that completed or were terminated, 30 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 6 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
13 studies in Hypercholesterolemia by Regeneron Pharmaceuticals: none open now, 1 under way, none of them phase 3. Of 12 finished, 10 (83%) have results posted.
Among the 13 studies in Hypercholesterolemia by Regeneron Pharmaceuticals, this one is the 4th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2026, is one of 5 in phase 2, and was the 13th registered.
Regeneron Pharmaceuticals’s Hypercholesterolemia studies by the year they started, since 2010.
2 of the studies testing alirocumab in Hypercholesterolemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477704Regeneron PharmaceuticalsA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | 2026-12-29 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing alirocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Regeneron Pharmaceuticals’s 13 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is researching an experimental drug called alirocumab, referred to as "study drug". In the United States, alirocumab is approved for the treatment of hypercholesterolemia (high blood cholesterol levels).
The aim of the study is to see how safe and effective alirocumab is when given weekly to adult participants who have hypercholesterolemia.
The study is looking at several other research questions, including:
Key Inclusion Criteria:
1. Participant has elevated LDL-C level, as defined in the protocol
Key Exclusion Criteria:
NOTE: Other Protocol-Defined Inclusion/Exclusion Criteria Apply
Drug: Alirocumab
Drug: Alirocumab
Drug: Alirocumab
Drug: Alirocumab
Administered per the protocol
Also known as: Praluent®, REGN727, SAR236553
Percent change in LDL-C
Time frame: From Baseline through Week 12
Concentrations of total alirocumab in serum
Time frame: Through Week 20
Concentrations of free Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) in serum
Time frame: Through Week 20
Percent change in LDL-C
Time frame: From Baseline through Week 8
Percent change in total cholesterol
Time frame: From Baseline through Week 12
Percent change in non-High-Density Lipoprotein-Cholesterol (HDL-C)
Time frame: From Baseline through Week 12
Percent change in HDL-C
Time frame: From Baseline through Week 12
Percent change in triglycerides
Time frame: From Baseline through Week 12
Percent change in Apolipoprotein B (ApoB)
Time frame: From Baseline through Week 12
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Time frame: Through Week 20
Severity of TEAEs
Time frame: Through Week 20
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.
Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's planned 6 months is below that.
Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab